Core Viewpoint - American Public Education, Inc. (APEI) is expected to report first-quarter 2025 results on May 12, with positive trends in enrollment and revenue growth anticipated despite some pressure on margins [1][3][7]. Revenue and Enrollment - APEI's first-quarter revenues are projected to increase by 4-6% year over year, reaching between $161 million and $163 million [4]. - The Zacks Consensus Estimate for first-quarter revenues is set at $161.9 million, indicating a 4.9% year-over-year rise [2]. - Strong enrollment growth is expected across all segments, particularly in the American Public University System (APUS), which accounted for 50.8% of total revenues in the previous quarter, and the Hondros College of Nursing (HCN) segment, which accounted for 10.8% [3][5]. Segment Performance - APUS is expected to have net course registrations between 100,500 and 102,000, reflecting a growth of 1.5-3% year over year [5]. - HCN's total enrollment is anticipated to increase by 10% to 3,600 students, while Rasmussen University (RU) is expected to see a 7% increase in enrollment to 14,500 students [5]. - Revenue growth predictions for APUS and HCN segments are 2.1% to $82.3 million and 9.5% to $18 million, respectively, while RU's revenue is expected to grow by 7.9% to $57.3 million [6]. Earnings and Margins - APEI expects net income to be between $1.7 million and $3.1 million, compared to a loss of $1 million a year ago [7]. - Adjusted EPS is anticipated to be between 9 cents and 17 cents, improving from a loss of 6 cents reported in the previous year [7]. - Adjusted EBITDA is projected to be between $13.5 million and $15.5 million, reflecting a decline of 21-9% year over year, with adjusted EBITDA margins expected to decrease by 170 basis points to 9.3% [7][8].

Core Viewpoint - Topgolf Callaway Brands (MODG) is expected to report a quarterly loss of $0.04 per share, a decline of 144.4% year-over-year, with revenues projected at $1.06 billion, down 7.4% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised 3% lower in the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts forecast 'Net Revenues by Category- Gear, Accessories & Other' to reach $108.97 million, reflecting a year-over-year decrease of 2.6% [5]. - 'Net Revenues by Category- Apparel' is expected to be $156.51 million, indicating a decline of 1.9% year-over-year [5]. - 'Net Revenues by Category- Venues' is projected at $379.66 million, down 6.4% from the prior year [5]. - 'Net Revenues- Topgolf' is estimated to be $396.01 million, a decrease of 6.3% from the year-ago quarter [6]. - 'Net Revenues- Golf Equipment' is expected to reach $444.44 million, reflecting a year-over-year change of -1.2% [6]. - 'Net Revenues- Active Lifestyle' is projected at $265.76 million, down 2.1% from the previous year [7]. - 'Net Revenues by Category- Golf Balls' is expected to be $98.92 million, indicating a decline of 4.9% year-over-year [7]. - 'Net Revenues by Category- Golf Clubs' is projected at $345.27 million, a slight decrease of 0.2% from the prior year [8]. - 'Net Revenues- Services' is estimated at $392.88 million, reflecting a year-over-year change of -6% [8]. - 'Net Revenues- Products' is expected to reach $689.28 million, indicating a decline of 5.1% year-over-year [8]. Operating Income - The consensus estimate for 'Operating income (loss)- Golf Equipment' stands at $76.50 million, compared to $82.10 million from the previous year [9]. Stock Performance - Over the past month, shares of Topgolf Callaway have returned +9.9%, while the Zacks S&P 500 composite has changed by +11.3% [9].

Core Viewpoint - Analysts expect Alcon to report quarterly earnings of $0.76 per share, reflecting a year-over-year decline of 2.6%, with revenues projected at $2.51 billion, an increase of 2.7% from the previous year [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1][2] Key Metrics Projections - Analysts estimate 'Net Sales- Total Surgical' to be $1.38 billion, representing a year-over-year increase of 2.8% [3] - The forecast for 'Net Sales- Total Vision Care' is $1.14 billion, indicating a year-over-year change of 2.7% [4] - 'Net Sales- Total Surgical- Consumables' is projected to reach $717.01 million, reflecting a 4.5% increase from the prior year [4] - 'Net Sales- Total Surgical- Equipment/other' is expected to be $223.04 million, showing a 1.8% year-over-year change [4] - 'Net Sales- Total Vision Care- Contact lenses' is anticipated to be $693.41 million, indicating a 3.3% increase from the previous year [5] - 'Net Sales- Total Vision Care- Ocular health' is projected at $441.87 million, reflecting a year-over-year change of 1.6% [5] - 'Net Sales- Total Surgical- Implantables' is expected to reach $435.74 million, indicating a 0.6% increase from the prior year [6] - The consensus for 'Revenues- Other revenues' stands at $17.50 million, reflecting a significant year-over-year increase of 16.7% [6] - 'Net sales by region- International' is projected to be $1.39 billion, indicating a 7.4% increase from the previous year [6] Stock Performance - Alcon shares have increased by 6.8% over the past month, compared to an 11.3% increase in the Zacks S&P 500 composite, with a Zacks Rank of 3 (Hold), suggesting expected performance in line with the overall market [7]

Core Insights - Primerica reported revenue of $803.56 million for Q1 2025, an increase of 8.4% year-over-year, with an EPS of $5.02 compared to $3.91 a year ago, exceeding both revenue and EPS consensus estimates [1][3] Financial Performance - Revenue surprise was +2.06% over the Zacks Consensus Estimate of $787.37 million, while the EPS surprise was +5.24% over the consensus estimate of $4.77 [1] - Primerica's stock has returned +7.9% over the past month, underperforming the Zacks S&P 500 composite's +10.6% change [3] Key Metrics - Life-Licensed Sales Force at the end of the period was 152,167, slightly above the average estimate of 152,073 [4] - Life Insurance Policies Issued totaled 86,415, below the average estimate of 90,432 [4] - Recruits numbered 100,867, compared to the average estimate of 111,314 [4] - Average Client Asset Values were $113 billion, in line with the average estimate of $113.01 billion [4] Revenue Breakdown - Revenues from Commissions and Fees were $296.96 million, exceeding the estimate of $276.77 million, representing a +16.4% year-over-year change [4] - Revenues from Other, net, were $17.13 million, slightly below the estimate of $17.34 million, showing a -1.6% year-over-year change [4] - Net Premiums revenue was $448.32 million, slightly below the estimate of $451.57 million, with a +4% year-over-year change [4] - Adjusted Operating Revenues from Investment and Savings Products were $290.81 million, exceeding the estimate of $271.16 million, with a +19.3% year-over-year change [4] - Adjusted Operating Revenues from Term Life Insurance were $457.84 million, below the estimate of $464.46 million, with a +4% year-over-year change [4] - Net Investment Income was $41.67 million, exceeding the estimate of $39.77 million, representing a +10.2% year-over-year change [4] - Adjusted Operating Revenues from Corporate and Other Distributed Products were $54.90 million, above the estimate of $52.47 million, with an +8.4% year-over-year change [4] - Direct Premiums revenue was $858.85 million, below the estimate of $863.84 million, with a +2.1% year-over-year change [4]

Company Overview - Oculis Holding AG (OCS) is expected to report a year-over-year decline in earnings with a projected loss of $0.51 per share, reflecting a change of -15.9% compared to the previous year [3] - Revenues are anticipated to remain flat at $0.22 million, unchanged from the year-ago quarter [3] Earnings Expectations - The consensus EPS estimate has been revised 5.01% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Oculis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -7.32%, suggesting a bearish outlook on earnings prospects [10][11] Historical Performance - Oculis has not been able to beat consensus EPS estimates in any of the last four quarters, with the last reported quarter showing a surprise of -58.33% [12][13] Market Reaction - The stock may experience upward movement if the actual results exceed expectations, while a miss could lead to a decline [2] - The combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict an earnings beat for Oculis [11][16]

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Fidelis Insurance Holdings (FIHL) despite an increase in revenues when it reports its results for the quarter ended March 2025 [1][3]. Earnings Expectations - The consensus EPS estimate for the upcoming report is a loss of $0.43 per share, reflecting a significant year-over-year decline of 158.1% [3]. - Revenues are projected to reach $656.08 million, which represents a 26.2% increase compared to the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 2.53%, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Fidelis Insurance is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -16.28%, suggesting a bearish outlook from analysts [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with positive readings being more reliable [7][8]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of delivering a positive surprise [8]. Historical Performance - In the last reported quarter, Fidelis Insurance was expected to post a loss of $1.08 per share but delivered a loss of $1.05, resulting in a positive surprise of 2.78% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [13]. Conclusion - Fidelis Insurance does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding this stock ahead of its earnings release [16].

Blue Bird Corporation (BLBD) is slated to release second-quarter fiscal 2025 results on May 7, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter's earnings per share (EPS) and revenues is pegged at 96 cents and $390 million, respectively. For the fiscal second quarter, the consensus estimate for Blue Bird's earnings has moved up 4 cents in the past 90 days. Its bottom-line estimates imply 7.87% growth from the year-ago reported numbers. The Zacks Consensus Estimate for BLBD ...

Core Insights - Charles River Laboratories International, Inc. (CRL) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.34, a 3.1% increase year over year, exceeding the Zacks Consensus Estimate by 13.6% [1] - Total revenues for the first quarter reached $984.2 million, surpassing the Zacks Consensus Estimate by 5.2%, but reflecting a 2.4% decline from the previous year [2] - The company raised its 2025 guidance, indicating improved net bookings in the Discovery and Safety Assessment (DSA) segment [12] Financial Performance - The gross profit for the quarter was $317.7 million, down 7.9% from the prior year, with a gross margin of 32.3%, contracting 181 basis points year over year [7] - Selling, general & administrative expenses decreased by 4.6% year over year to $177.8 million, while adjusted operating profit fell 11.7% to $139.9 million [7] - The company exited the first quarter with cash and cash equivalents of $229.4 million, an increase from $194.6 million at the end of the previous quarter [8] Segment Performance - Research Models and Services (RMS) revenues totaled $213.1 million, down 3.5% year over year, primarily due to timing of shipments in China and lower revenues in the Cell Solutions business [4] - Discovery and Safety Assessment (DSA) revenues amounted to $592.6 million, a decline of 2.1% year over year, attributed to lower revenues for discovery services [5] - Manufacturing Solutions revenues were $178.5 million, down 3.6% year over year, mainly due to declines in CDMO and Biologics Testing businesses [6] Shareholder Returns - During the first quarter, the company repurchased 2.1 million shares for a total of $350 million, with a remaining authorization of $549.3 million under its $1 billion stock repurchase program [9] 2025 Guidance - For 2025, CRL expects total revenues to decline in the range of 5.5%-3.5%, an improvement from the earlier estimate of 4.5%-7% [10] - Adjusted EPS for 2025 is projected to be in the range of $9.30-$9.80, up from the previous range of $9.10-$9.60 [11]

Core Viewpoint - ACI Worldwide (ACIW) is expected to report significant growth in quarterly earnings and revenues, indicating strong performance compared to the previous year [1]. Financial Performance - Quarterly earnings are predicted to be $0.33 per share, reflecting a 230% increase year-over-year [1]. - Revenues are forecasted to reach $364.85 million, representing a 15.5% increase compared to the same period last year [1]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [1]. Revenue Breakdown - 'Revenues- Banks' are expected to reach $134.10 million, a change of +27.2% from the prior-year quarter [4]. - 'Revenues- Billers' are projected to be $192.40 million, indicating a +10% change from the year-ago quarter [4]. - 'Revenues- Merchants' are anticipated to come in at $38.40 million, reflecting a +7.6% change from the previous year [4]. Market Performance - ACI Worldwide shares have increased by +13.4% in the past month, outperforming the Zacks S&P 500 composite's +10.6% increase [5]. - The company holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the overall market in the near term [5].

Core Viewpoint - Petrobras is expected to report a decline in revenues for Q1 2025, with earnings per share (EPS) estimates revised downward by 14% over the past month, indicating a challenging operational environment despite a projected year-over-year improvement in EPS [1][16]. Financial Performance - The Zacks Consensus Estimate for Q1 2025 EPS is 92 cents, with revenues expected to be $21.7 billion, reflecting an 8.7% year-over-year decrease [1][2]. - For the full year 2025, the revenue estimate is $83.9 billion, indicating an 8.2% decline year-over-year, while the EPS estimate is $2.79, suggesting a contraction of approximately 6.4% [2][3]. Production and Sales - Petrobras is projected to experience a marginal 0.2% year-over-year drop in oil and gas production to 2.77 million barrels of oil equivalent per day (boed) in Q1 2025, with crude oil output declining by 1% to 2.21 million barrels per day (bpd) [7]. - Total oil, gas, and derivatives sales decreased by 1.9% to 2.86 million boed, with exports falling 10.4% year-over-year to 760,000 bpd, primarily due to reduced shipments to China and the U.S. [8]. Market Position and Valuation - Petrobras stock has declined by 12% year-to-date, underperforming compared to American supermajors like ExxonMobil and Chevron [9]. - The stock trades at a forward price-to-earnings (P/E) ratio of 4.10, significantly lower than ExxonMobil and Chevron, which trade around 15X earnings, reflecting concerns over political risks and government influence [13]. Economic and Market Conditions - The company's earnings are closely tied to oil prices, which are trending lower amid recession fears and geopolitical tensions, potentially impacting revenue and margins [15]. - The broader economic slowdown could further squeeze margins, with Petrobras facing challenges in maintaining dividend potential amidst high-cost exploration plans and increasing capital expenditures [15][17].